FDA Committee Recommends Amgen’s Enbrel For Approval In Pediatric Psoriasis
Panel sees benefit of giving physicians freedom to choose the treatment and gaining further data through Amgen’s proposed safety registry and ongoing study.
Panel sees benefit of giving physicians freedom to choose the treatment and gaining further data through Amgen’s proposed safety registry and ongoing study.